Wataru Ito, Tatsuya Fukumori, Nao Asaoka, Natsuko Imakita, Tomoko Nishimura, Ryutaro Furukawa, Yuji Nishihara, Hiroyuki Fujikura, Takahiro Sekine, Naoki Yamaguchi, Yuichiro Hirata, Sho Miyamoto, Takayuki Kanno, Harutaka Katano, Tadaki Suzuki, Kei Kasahara
Immunocompromised patients with hematologic malignancies, particularly those treated with anti-CD20 antibodies such as rituximab and obinutuzumab, are known to be at risk of prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Prolonged administration or combination therapy with antiviral medications reportedly yields favorable outcomes in these patients. However, knowledge regarding the adverse events associated with such therapeutic approaches is limited. Herein, we report a case of acute acalculous cholecystitis (AAC) following extended administration of nirmatrelvir/ritonavir (NMV/r) in a 68-year-old Japanese man with persistent SARS-CoV-2 infection...
January 4, 2024: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy